**Core Concept**
Haloperidol-induced extrapyramidal side effects (EPS) are a consequence of dopamine receptor blockade, specifically at D2 receptors in the nigrostriatal pathway. This blockade disrupts the balance between dopamine and acetylcholine, leading to abnormal movement disorders.

**Why the Correct Answer is Right**
The correct treatment involves addressing the underlying dopamine receptor blockade. Benzatropine, an anticholinergic agent, works by increasing the availability of acetylcholine in the synapse, thereby countering the imbalance caused by haloperidol. This mechanism helps to alleviate EPS symptoms such as dystonia, akathisia, and parkinsonism.

**Why Each Wrong Option is Incorrect**
**Option A:** Haloperidol dose reduction is not a direct treatment for EPS, as it may not address the underlying receptor blockade.
**Option B:** Olanzapine, an atypical antipsychotic, may actually exacerbate EPS due to its weak affinity for D2 receptors and strong affinity for serotonin receptors.
**Option C:** Clonazepam, a benzodiazepine, is not a first-line treatment for EPS, as it may not directly address the dopamine-acetylcholine imbalance.

**Clinical Pearl / High-Yield Fact**
When treating EPS, it's essential to use anticholinergic agents like benzatropine as a first-line treatment, as they directly counteract the dopamine receptor blockade caused by typical antipsychotics like haloperidol.

**Correct Answer: B. Benzatropine**